|
Fig. 2 Effect of (a)–(c) Convolamine (Cm) and (d), (e) Convolvine (Cv) on the hyperlocomotor response of 5 dpf wfs1abWT and wfs1abKO mutant zebrafish larvae. (a), (d) VMR activity profiles. The activity is measured for 70 min, with 30 min of training in the dark (OFF), then 2 cycles of light/dark (ON/OFF) of 10 min each. (b), (c), (e) Analysis of the distance traveled by 5 dpf wfs1abWT and wfs1abKO larvae during the light/dark cycle in the VMR test as averaged differences between the OFF and ON phases. Data show mean ± SEM with n = 8–12 in (a), (b), n = 9–12 in (c), n = 9–20 in (d), (e). Two-way ANOVAs: F(1,72) = 320.3, p < 0.0001 for the genotype, F(3,72) = 43.24, p < 0.0001 for the treatment, F(3,72) = 47.43, p < 0.0001 for the interaction in (b); F(1,72) = 54.79, p < 0.0001 for the genotype, F(1,72) = 13.19, p < 0.0001 for the treatment, F(3,72) = 8.161, p < 0.0001 for the interaction in (c); F(1,54) = 152.9, p < 0.0001 for the genotype, F(1,54) = 10.13, p = 0.0002 for the treatment, F(3,54) = 6.636, p = 0.0027 for the interaction in (e). * p < 0.05, ** p < 0.01, *** p < 0.01 versus V-treated wfs1abWT group; # p < 0.05, ## p < 0.01, ### p < 0.0001 versus V-treated wfs1abKO group; Dunnett's test.